文献速递临床试验与 GCP流行病学与生物统计

口服糖皮质激素治疗成人感染后咳嗽:OSPIC试验方案

Oral corticosteroids for post-infectious cough in adults: study protocol for a double-blind randomized placebo-controlled trial in Swiss family practices (OSPIC trial).
PubMed 文献 · Trials · 2020-11-23

感染后咳嗽(上呼吸道感染后持续3–8周)在初级保健中缺乏一致的治疗推荐。OSPIC试验是首个评估口服糖皮质激素对此病症有效性的随机对照试验,采用三盲、多中心、优效性设计,计划在瑞士纳入204例成人患者,随机接受5天口服糖皮质激素或安慰剂,主要结局为随机化后14天莱斯特咳嗽问卷评分。

要点

  • 感染后咳嗽指上呼吸道感染后持续3–8周的咳嗽,可严重影响生活质量。
  • 现有治疗证据不足,口服糖皮质激素的获益与安全性尚未在随机试验中验证。
  • OSPIC试验将为首个评估口服糖皮质激素治疗感染后咳嗽的随机对照试验。

核心结论

  • OSPIC试验旨在评估口服糖皮质激素对成人感染后咳嗽的有效性和安全性。

研究设计与样本

  • 三盲、随机对照、多中心、优效性试验,在瑞士初级保健诊所开展。
  • 计划纳入204例因上呼吸道感染后咳嗽持续3–8周就诊的成人患者。
  • 参与者随机接受5天口服糖皮质激素或安慰剂治疗。

主要发现

  • 主要结局为随机化后14天莱斯特咳嗽问卷评分评估的咳嗽相关生活质量。
  • 次要结局包括多个时间点的咳嗽相关生活质量、咳嗽总体消失及不良事件。

关键数值与推荐

  • 纳入标准:上呼吸道感染后咳嗽持续3–8周的成人患者。
  • 干预方案:口服糖皮质激素5天,对照为安慰剂。
  • 主要结局评估时间:随机化后14天。

临床怎么用

  • 该试验结果可为感染后咳嗽的循证治疗提供依据,可能减少患者再就诊和止咳药支出。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cough is a common reason for patients to visit general practices. So-called post-infectious cough is defined as lasting 3 to 8 weeks after an upper respiratory tract infection. It can be disabling in daily activities, with substantial impact on physical and psychosocial health, leading to impaired quality of life and increased health care costs. Recommendations for the management of post-infectious cough in primary care are scarce and incoherent. A systematic review and meta-analysis of randomized clinical trials (RCT) assessing patient-relevant benefits and potential harms of available treatments identified six eligible RCTs assessing different treatment regimens (i.e. inhaled fluticasone propionate, inhaled budesonide, salbutamol plus ipratropium-bromide, montelukast, nociception-opioid-1-receptor agonist, codeine, gelatine). No RCT found clear patient-relevant benefits and most had an unclear or high risk of bias. Post-infectious cough is thought to be mediated by inflammatory processes that are also present in exacerbations of asthma or chronic obstructive pulmonary diseases for which there is strong evidence that oral corticosteroids provide patient-relevant benefit without relevant harm. We therefore plan to conduct the first RCT evaluating the effectiveness of oral corticosteroids for post-infectious cough. METHODS: We are conducting a triple-blinded randomized-controlled and multicentred superiority trial in primary health care practices in Switzerland. We will include 204 adult patients who consult their general practitioner (GP) for a cough lasting 3 to 8 weeks following an upper respiratory tract infection. Participants will be randomly allocated to either the 5-day treatment with oral corticosteroids or placebo. The primary outcome is cough-related quality of life assessed by the Leicester Cough Questionnaire score 14 days after randomization. Secondary outcomes include cough-related quality of life at several time points, overall cessation of cough and adverse events. DISCUSSION: This RCT will provide evidence on whether oral corticosteroids are beneficial and safe in patients with post-infectious cough. Results can have a substantial impact on the well-being and management of these patients in Switzerland and beyond. An evidence-based treatment for this condition may reduce re-consultations with GPs and spending for antitussive drugs, thus possibly having an impact on health care spending. TRIAL REGISTRATION: ClinicalTrials.gov NCT04232449 . Prospectively registered on 18 January 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Merlo C, Essig S, Brancati-Badarau DO, et al. Oral corticosteroids for post-infectious cough in adults: study protocol for a double-blind randomized placebo-controlled trial in Swiss family practices (OSPIC trial). Trials. 2020. PMID: 33225983. doi:10.1186/s13063-020-04848-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。